MeiraGTx Holdings plc (MGTX)
Summary
What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near
Stuart Naylor liquidated 27,659 shares for $409,000 on July 7, 2026, at a weighted average price of $14.80 per share. The transaction resulted in a 4% reduction of the insider's total direct equity holdings in the company.
MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?
MeiraGTx (MGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
MeiraGTx: The Market Is Missing The Manufacturing Pivot
MeiraGTx is evolving into a late-stage, manufacturing-enabled genetic medicine company with multiple near-term regulatory catalysts. MGTX's robust manufacturing infrastructure and targeted therapies, such as Bota-vec and AAV2-hAQP1, position it for commercial inflection without mass-market commercialization burdens. Recent equity raise and anticipated milestone payments extend MGTX's cash runway through 2H 2028, supporting execution of late-stage programs.
MeiraGTx Holdings plc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 185 | $1,209.55 | $2,266.25 | $1,056.7 | 87.36% |
| ML Marc Larkins Johnson & Johnson | 6.64M | $62.6M | $81.35M | $18.75M | 29.95% |
| BG Bart Gancher Intech Investment Management LLC | 10,413 | $70,600.14 | $127,142.73 | $56,542.59 | 80.09% |
 Point72 Asset Management LP Point72 Asset Management LP | 70,953 | $614,453 | $866,336.13 | $251,883.13 | 40.99% |
| PF Phillip Fitzsimmons Hennion & Walsh Asset Management Inc. | 421,979 | $3.68M | $5.15M | $1.47M | 39.93% |
MeiraGTx Holdings plc (MGTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has MeiraGTx Holdings plc ever had a stock split?
MeiraGTx Holdings plc Profile
| Biotechnology Industry | Healthcare Sector | Alexandria Forbes CEO | NASDAQ (NGS) Exchange | G59665102 CUSIP |
| US Country | 409 Employees | - Last Dividend | - Last Split | 8 Jun 2018 IPO Date |
Overview
MeiraGTx Holdings plc represents a pioneering force in the biotechnology sector, focusing specifically on the ambitious field of gene therapy. As a clinical stage enterprise, it dedicates its resources to forging revolutionary treatments aimed at a spectrum of serious diseases. This innovative company, incorporated in 2015 and headquartered in New York, New York, stands out through its commitment to addressing a variety of complex health challenges through advanced genetic interventions. With a strategic partnership with Janssen Pharmaceuticals, Inc., MeiraGTx is at the forefront of research, development, and potential commercialization of gene therapies, particularly targeting inherited retinal diseases and potentially revolutionizing ocular health and beyond.
Products and Services
- Ocular Diseases Treatments
Specializing in the field of ocular health, MeiraGTx is developing transformative therapies aimed at inherited retinal diseases and a broader segment of degenerative eye diseases. This includes working on cures for conditions that have long been considered untreatable, providing hope for those affected by vision impairment and blindness due to genetic origins.
- Neurodegenerative Diseases Therapies
The company extends its groundbreaking work to the realm of neurodegenerative disorders, offering new possibilities for treatment modalities. Through gene therapy, MeiraGTx aims to tackle the underlying genetic causes of these diseases, potentially slowing, halting, or even reversing the progression of conditions that severely impact cognitive and motor functions.
- Xerostomia Treatment
Addressing the often overlooked but significant issue of xerostomia, commonly known as dry mouth and frequently induced by radiation therapy, MeiraGTx is advancing clinical trials to offer relief and improve the quality of life for cancer survivors. Its innovative approach seeks to restore salivary gland function through gene therapy, marking a significant leap forward in supportive care for oncology patients.
- Clinical Development Programs
- Achromatopsia
In the clinical development pipeline, MeiraGTx is conducting Phase I/II trials for treatments targeting achromatopsia, a rare inherited condition that affects vision, making it difficult for individuals to see color and detail.
- X-linked Retinitis Pigmentosa
The company's commitment to ocular diseases includes advancing a clinical stage program for X-linked retinitis pigmentosa, aiming to tackle this genetic disorder that causes progressive vision loss, enhancing understanding and treatment through gene therapy research.
- RPE65-deficiency
Also in Phase I/II clinical trial stages, therapies for RPE65-deficiency are being explored, with the goal of correcting this specific genetic fault known to cause blindness, representing another facet of MeiraGTx's efforts to combat inherited retinal diseases.
- Radiation-induced Xerostomia
With Phase I clinical trials underway, the company's research into radiation-induced xerostomia showcases its initiative to tackle side effects of cancer treatment through innovative gene therapy, aiming to provide effective management and recovery of salivary gland function.
- Parkinson's Program
Reflecting its diversification into neurodegenerative diseases, MeiraGTx has completed a Phase II trial for a Parkinson's disease program, underlining its commitment to exploring gene therapy as a potential therapeutic strategy for managing and possibly altering the course of this challenging condition.
- Achromatopsia
